20 May 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using lumasiran in the context of national commissioning by NHS England.

Lumasiran sodium is not recommended, within its marketing authorisation, for the treatment of patients with primary hyperoxaluria type 1.

Read NICE evaluation consultation document